Literature DB >> 18377911

Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis.

Valerie Clerin1, Heather H Shih, Nanhua Deng, Gustave Hebert, Christine Resmini, Kathleen M Shields, Jeffrey L Feldman, Aaron Winkler, Leo Albert, Vasu Maganti, Anthony Wong, Janet E Paulsen, James C Keith, George P Vlasuk, Debra D Pittman.   

Abstract

OBJECTIVE: The present study was conducted to characterize the expression of the cysteine protease legumain in murine and human atherosclerotic tissues, and to explore the molecular mechanisms by which legumain may contribute to the pathophysiology of atherosclerosis. METHODS AND
RESULTS: Using microarray analysis, legumain mRNA expression was found to increase with development of atherosclerosis in the aorta of aging Apolipoprotein E deficient mice while expression remained at low level and unchanged in arteries of age-matched C57BL/6 control mice. In situ hybridization and immunohistochemical analysis determined that legumain was predominantly expressed by macrophages in the atherosclerotic aorta, in lesions at the aortic sinus and in injured carotid arteries of Apolipoprotein E deficient mice as well as in inflamed areas in advanced human coronary atherosclerotic plaques. In vitro, M-CSF differentiated human primary macrophages were shown to express legumain and the protein could also be detected in the culture media. When tested in migration assays, legumain induced chemotaxis of primary human monocytes and human umbilical vein endothelial cells.
CONCLUSIONS: Legumain is expressed in both murine and human atherosclerotic lesions. The macrophage-specific expression of legumain in vivo and ability of legumain to induce chemotaxis of monocytes and endothelial cells in vitro suggest that legumain may play a functional role in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18377911     DOI: 10.1016/j.atherosclerosis.2008.01.016

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  20 in total

1.  Synthesis and evaluation of aza-peptidyl inhibitors of the lysosomal asparaginyl endopeptidase, legumain.

Authors:  Jiyoun Lee; Matthew Bogyo
Journal:  Bioorg Med Chem Lett       Date:  2011-12-21       Impact factor: 2.823

2.  Counter Selection Substrate Library Strategy for Developing Specific Protease Substrates and Probes.

Authors:  Marcin Poreba; Rigmor Solberg; Wioletta Rut; Ngoc Nguyen Lunde; Paulina Kasperkiewicz; Scott J Snipas; Marko Mihelic; Dusan Turk; Boris Turk; Guy S Salvesen; Marcin Drag
Journal:  Cell Chem Biol       Date:  2016-07-28       Impact factor: 8.116

3.  Unraveling the transcriptional determinants of liver sinusoidal endothelial cell specialization.

Authors:  Willeke de Haan; Cristina Øie; Mohammed Benkheil; Wouter Dheedene; Stefan Vinckier; Giulia Coppiello; Xabier López Aranguren; Manu Beerens; Joris Jaekers; Baki Topal; Catherine Verfaillie; Bård Smedsrød; Aernout Luttun
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-03-02       Impact factor: 4.052

4.  Gene expression signatures differ with extent of atherosclerosis in monkey iliac artery.

Authors:  Kathleen M Eyster; Susan E Appt; Connie J Mark-Kappeler; Abha Chalpe; Thomas C Register; Thomas B Clarkson
Journal:  Menopause       Date:  2011-10       Impact factor: 2.953

5.  Role of Asparagine Endopeptidase in Mediating Wild-Type p53 Inactivation of Glioblastoma.

Authors:  Yingying Lin; Keman Liao; Yifeng Miao; Zhongrun Qian; Zhaoyuan Fang; Xi Yang; Quanmin Nie; Gan Jiang; Jianhua Liu; Yiyi Yu; Jieqing Wan; Xiaohua Zhang; Yaomin Hu; Jiyao Jiang; Yongming Qiu
Journal:  J Natl Cancer Inst       Date:  2020-04-01       Impact factor: 13.506

6.  The asparaginyl endopeptidase legumain after experimental stroke.

Authors:  Taku Ishizaki; Agnes Erickson; Enida Kuric; Mehrdad Shamloo; Ikuko Hara-Nishimura; Ana Rita Lourenço Inácio; Tadeusz Wieloch; Karsten Ruscher
Journal:  J Cereb Blood Flow Metab       Date:  2010-03-17       Impact factor: 6.200

7.  The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity.

Authors:  Krishna Mohan Bajjuri; Yuan Liu; Cheng Liu; Subhash C Sinha
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

8.  Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain.

Authors:  Jiyoun Lee; Matthew Bogyo
Journal:  ACS Chem Biol       Date:  2010-02-19       Impact factor: 5.100

9.  Functional imaging of legumain in cancer using a new quenched activity-based probe.

Authors:  Laura E Edgington; Martijn Verdoes; Alberto Ortega; Nimali P Withana; Jiyoun Lee; Salahuddin Syed; Michael H Bachmann; Galia Blum; Matthew Bogyo
Journal:  J Am Chem Soc       Date:  2012-12-18       Impact factor: 15.419

Review 10.  Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases.

Authors:  Zhentao Zhang; Manling Xie; Keqiang Ye
Journal:  Expert Opin Ther Targets       Date:  2016-05-13       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.